ECD Automotive Design Stock (NASDAQ: ECDAW)

Latest news for ECD Automotive Design (NASDAQ:ECDAW) Stock

ECD Automotive Design Inc is a custom-car builder in the Restomod sector with a focus on British classic motor vehicles of various models of both two-door and four-door styles. The company has established a facility geared towards producing the most customized Land Rovers with the highest quality of parts and the highest quality labor force building each vehicle. ECD restores Land Rovers Defenders, Land Rover Series IIA, the Range Rover Classic and the Jaguar E-Type. It upgrade any engine, including Chevrolet V8's, Land Rover V8's, Cummins diesel engines and new electric drivetrains, performing all the necessary body work, drivetrain selection and installation, every stitch in the interior, paint work, up to placement of the last nut and bolt.

ECD Automotive Design Inc

Macro Economic Events

News

Econ #s

Economics

U.K. Interest Rate Decision For December Unchanged At 4.75%

WIIM

Accenture shares are trading higher after the company reported better-than-expected Q1 financial results and raised FY25 revenue growth outlook.

Northland Capital Markets analyst Mike Grondahl maintains Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Outperform and raises the price target from $300 to $360.

Price Target

Analyst Ratings

SEZL

Northland Capital Markets Maintains Outperform on Sezzle, Raises Price Target to $360

In addition, IAS is launching its AI-driven Total Media Quality (TMQ) for Kwai product suite to provide advertisers with industry-leading Viewability and Invalid Traffic (IVT) Measurement.

Integral Ad Science Enters Exclusive First-To-Market Content-Level Brand Safety And Suitability Measurement For Advertisers On Kwai For Business

The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex System) and liquid chromatography-mass spectrometry (BioAccord LC-MS System from Waters) to deliver innovative solutions that optimize workflows, improve precision, and accelerate development timelines.

Health Care

Contracts

General

TECH

Bio-Techne Announced Co-marketing And Co-Promotion Agreement With Waters Corporation Aimed At Expanding The Reach Of Advanced Biotherapeutic Characterization And Development Processes

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and raises the price target from $5 to $6.

CGTX

HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Raises Price Target to $6

Darden Restaurants shares are trading higher after the company reported better-than-expected Q2 EPS and issued better-than-expected FY25 revenue outlook.

These actions will follow the previously announced sale of Viad's GES business, which is expected to close on December 31, 2024.&nbsp;
Following the sale of GES, the Company's remaining business, Pursuit, will stand alone as a publicly traded company with a new name and common stock ticker reflective of the ongoing attractions and hospitality business.

Viad Plans To Change Its Corporate Name To Pursuit Attractions And Hospitality, Inc. Effective December 31, 2024; To Begin Trading Under New NYSE Ticker 'PRSU' On January 2, 2025

NIVF

NewGenIvf Announced That It Has Engaged OSL Digital Securities, As Part Of Newgen's Intent To Begin Investing In The Digital Assets Space. Following The Engagement, NewGen Has Transferred Funds In The Amount Of $1M To Its Account

Lamb Weston shares are trading lower after the company reported worse-than-expected Q2 earnings and lowered FY25 outlook.

Upon consummation of the Merger, Tripadvisor plans to retire approximately 27 million shares of Tripadvisor common stock currently held by Liberty TripAdvisor, net of approximately 2.4 million shares underlying the VPF.
Accordingly, Tripadvisor views this transaction as effectively a repurchase of the Tripadvisor common stock held by Liberty TripAdvisor.&nbsp;
The implied share price for the acquisition of such shares of Tripadvisor common stock from Liberty Tripadvisor is $16.21 (which reflects a premium of approximately 16% based on the 10-day volume-weighted average share price as of December 17, 2024).
The transaction will result in the simplification of Tripadvisor's capital structure into a single class of shares with no controlling stockholder, thereby creating more strategic flexibility for Tripadvisor.

LTRPA

TRIP

Tripadvisor Agrees To Acquire Liberty TripAdvisor; Aggregate Transaction Value Is Approximately $435M

Nic Carter, Founding Partner at Castle Island Ventures, has expressed skepticism about the U.S. establishing a <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42531359/is-a-bitcoin-strategic-reserve-a-good-idea-expert-pushes-back-just-buy-btc-yourself">strategic Bitcoin reserve</a> under the incoming Trump administration, citing risks to the dollar&#8217;s global standing.
What Happened: His view has sparked a sharp critique from Matthew Sigel, Head of Digital Assets Research at VanEck, who labeled Carter&#8217;s perspective as &#8220;Loserthink&#8221; in a pointed social media response.
In an interview with Bloomberg on Wednesday, Carter <a href="https://x.com/BloombergTV/status/1869133367611965454">said</a> that while he supports Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), he does not believe it would be prudent for the U.S. government to signal a shift away from its current monetary system.
Carter discussed the nuances of what constitutes a &#8220;<a href="https://www.benzinga.com/24/12/42522606/trump-is-serious-about-creating-a-bitcoin-reserve-says-microstrategys-michael-saylorurges-to-buy-btc-before-it-goes-up-by-100x">strategic reserve</a>,&#8221; distinguishing between merely holding onto seized Bitcoin and actively acquiring more, as proposed by some legislation.
He noted that while the former could be expected under Trump&#8217;s policy of maintaining current Bitcoin holdings, the latter—specifically Senator Cynthia Lummis&#8216; bill to buy one million Bitcoin over five years—is unlikely to gain Congressional support.
&#8220;The U.S. is the issuer of the global reserve currency. We shouldn&#8217;t do something that would call into question our own solvency,&#8221; Carter stated, highlighting the potential risks to global markets if the U.S. were seen as moving away from the dollar. 
He pointed out that while smaller nations like <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42387366/bitcoin-sellers-delight-bhutan-transfers-40m-in-btc-to-qcp-capital">Bhutan</a> or <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42397116/el-salvador-relaxes-bitcoin-rules-to-seal-13-billion-loan">El Salvador</a> might benefit from adopting Bitcoin, the same logic does not apply to the U.S. due to its pivotal role in the global financial system.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42561551/microstrategy-chairman-michael-saylor-eyes-intelligent-leverage-with-bitcoin-purchases">MicroStrategy Chairman Michael Saylor Eyes&#8217; Intelligent Leverage&#8217; With Bitcoin Purchases</a>
Why It Matters: Regarding Bitcoin&#8217;s recent price surge, which saw it briefly hit $108,000, Carter acknowledged the optimism around Trump&#8217;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42554929/donald-trump-reportedly-discussed-bitcoin-reserve-in-meeting-with-cryptocom-ceo-kris-marszalek">crypto-friendly policies</a> but warned of a potential market correction should expectations for a strategic reserve not materialize.
&#8220;The hardest thing about being a bitcoiner is you&#8217;re in the trade with a lot of delusional people,&#8221; he remarked, suggesting that the market might be pricing in overly optimistic scenarios.
In contrast, Sigel took to X to <a href="https://x.com/matthew_sigel/status/1869199409126559768">challenge</a> Carter&#8217;s caution, stating, &#8220;This is Loserthink. Should the US Government avoid any signals of fiscal restraint, then? In fact, why pretend at all—let's just print trillions more and see where that gets us.&#8221;
This retort suggests a critique of what Sigel perceives as an overly conservative approach to Bitcoin adoption, likening it to avoiding necessary fiscal discipline or innovation <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral#:~:text=Following%20the%20latest%2025%2Dbasis,the%20post%2Dmeeting%20press%20conference.">in monetary policy</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42560364/hong-kong-approves-four-new-crypto-exchanges-positioning-itself-as-a-key-hub-expert-says">Hong Kong Approves Four New Crypto Exchanges, &#8216;Positioning Itself As A Key Hub,&#8217; Expert Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Reserve Could Call US Solvency Into Question Critic Says, VanEck Exec Fires Back: 'This Is Loserthink'

AleAnna Secures A Contract To Sell Its Gas To Shell Energy Europe Ltd, A Leading Natural Gas, Power And Environmental Trading Company Across European Markets
<ul>
<li>AleAnna has signed a multi-year gas sales agreement with Shell Energy Europe Ltd for its share of the Longanesi production to ensure secure natural gas</li>
<li>Longanesi production is expected to commence in Q1 2025</li>
</ul>

Commodities

Markets

ANNA

Aleanna Has Signed An Exclusive Gas Supply Agreement With Shell Energy Europe

Needham analyst Quinn Bolton maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and lowers the price target from $140 to $120.

Needham Maintains Buy on Micron Technology, Lowers Price Target to $120

<ul>
<li>Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025</li>
<li>On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026</li>
<li>Preclinical data with ORKA-001 demonstrate the potential for once- or twice-yearly dosing, a significant improvement over standard of care</li>
</ul>

Biotech

ORKA

Oruka Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial Of ORKA-001, The Company's Novel, Subcutaneously Administered, Half-life Extended Monoclonal Antibody Targeting IL-23p19

U.S. stock futures climbed on Thursday in premarket hours after the indices declined in the previous session following a <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">hawkish cut</a> from the Federal Reserve. The futures of all four major indices were trading higher.
The 10-year and two-year Treasury notes yielded 4.54% and 4.32%, respectively.
On Wednesday, the Federal Reserve did reduce interest rates by 0.25% to a range of 4.25%-4.5%, as expected. However, the revised economic projections indicate only two possible rate cuts in 2025—down from the four predicted in September and fewer than the three that markets had anticipated before the meeting.
The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 91.4%, <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according</a> to CME Group&#8217;s FedWatch tool.
GDP revisions slated to be released later today will reveal whether the economy maintained the previously estimated 2.8% growth rate for the third quarter.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.28%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.40%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.37%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.39%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.52% to $589.35 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.48% to $518.94, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
U.S. stocks closed lower on Wednesday, with the <a href="https://www.benzinga.com/news/earnings/24/12/42569953/dow-dips-over-1100-points-falling-for-10th-session-as-powell-adopts-hawkish-stance-greed-index-moves-to-fear-zone">Dow Jones dropping for the tenth consecutive session</a>, falling by more than 1,100 points.
On the economic front, the U.S. posted a current account deficit of $310.9 billion in the third quarter, up from a revised deficit of $275.0 billion in the previous quarter and exceeding market expectations of a $284 billion gap. Meanwhile, U.S. housing starts declined by 1.8%, reaching an annualized rate of 1.289 million units in November, down from 1.312 million in October.
All sectors of the S&amp;P 500 ended the day in the red, with consumer discretionary, real estate, and communication services stocks seeing the largest losses.
&#8220;It&#8217;s been a very mild year with just 17 declines of 1% or more,&#8221; said Charlie Bilello, chief market strategist at Creative Planning Investor.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 fell 2.95% today, the worst day for stocks since August 5 (Nikkei black Monday crash). Overall, it&#39;s been a very mild year with just 17 declines of 1% or more (vs. 29 in the average year). History of large down days since 1928&#8230; <a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a><a href="https://t.co/l5IYmkf6Ih">https://t.co/l5IYmkf6Ih</a> <a href="https://t.co/XSAGBsgiIY">pic.twitter.com/XSAGBsgiIY</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1869527952851116382?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-3.56%</td>
<td>19,392.69</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-2.95%</td>
<td>5,872.16</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-2.58%</td>
<td>42,326.87</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-4.39%</td>
<td>2,231.51</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Talking about her 2025 projections after the Fed&#8217;s rate cut, Julia Khandoshko, the CEO of Mind Money in a conversation with <a href="https://www.benzinga.com">Benzinga</a> said, &#8220;In 2025, investors should focus on three key strategies: monitoring the impact of political and economic changes on markets, investing in promising sectors such as AI and biotechnology without excessive dependence on technology, and actively diversifying the portfolio with traditional industries and new opportunities in emerging markets.&#8221;
Chris Zaccarelli, chief investment officer for Northlight Asset Management, said that markets are forward-looking and reacted to the Fed&#8217;s 2025 projection and not the quarter-point cut that it delivered.
&#8220;Santa came early and dropped a 25-bps rate cut in the market&#8217;s stocking but accompanied it with a note saying that there would be coal next year,&#8221; Zaccarelli said.
Jeremy Siegel, professor emeritus at the University of Pennsylvania's Wharton School, described the stock market's recent downturn as a "healthy" reaction to the Federal Reserve's cautious approach to future interest rate cuts.
&#8220;The market was overly optimistic…so I am not surprised at the sell-off,&#8221; he said.
He suggested that the Fed might reduce rates only once or twice next year, with the possibility of no cuts at all due to inflation concerns. Siegel also mentioned potential tariffs from President-elect Donald Trump could impact inflation, though he believes the actual tariffs may not be as significant as feared.
Bill Adams, chief economist for Comerica Bank, said the Fed is reacting to the incoming Trump administration&#8217;s policies, which it sees as most likely to boost growth and inflation, as well as tighten the job market.
Trump does not have much control over the pace of rate cuts in the near term, Adams said, but &#8220;that could change in 2026 if President-elect Trump gets the Senate to confirm a new Fed chair who is more sympathetic to his policy goals.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released in the rest of the week that will help investors determine the future course of action.
<ul>
<li>On Thursday, the data for initial jobless claims till Dec. 14, GDP&#8217;s second revision for the third quarter, and Philadelphia Fed manufacturing survey data for December will be released at 8:30 a.m., ET.</li>
<li>Existing home sales data and U.S. leading economic indicators for November will be announced at 10:00 a.m., ET.</li>
<li>On Friday, personal income and spending data along with core and headline PCE index data for November will be released at 8:30 a.m., ET.</li>
<li>Consumer sentiment data for December will be released at 10:00 a.m., ET.</li>
<li>Carnival Corporation and Winnebago Industries will report earnings.</li>
</ul>
Stocks In Focus:
<ul>
<li>Accenture Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) was up 3.56% ahead of its Q1 earnings call scheduled before the opening bell. Wall Street expects quarterly earnings at $3.40 per share on revenue of $17.12 billion.</li>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) was down 15.52% after it posted better-than-expected earnings but sales missed expectations in the first quarter.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) was just up 0.4% in premarket a analysts expect it to post quarterly earnings at 64 cents per share on revenue of $12.13 billion after the closing bell.</li>
<li>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) was 8.85% lower in premarket trading after it reported worse-than-expected financial results for the fourth quarter.</li>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) was up 22.55% after it inked an agreement with Astellas Pharma allowing the latter to leverage Sangamo&#8217;s novel proprietary neurotropic adeno-associated virus capsid. Sangamo will receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees.</li>
<li>KULR Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) was up 27.88% after it announced plans to launch the KULR ONE Space battery via launch integrator Exolaunch on a SpaceX rideshare mission scheduled for 2026.</li>
<li>Mesoblast Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 42.61% in pre-market trading after Mesoblast's RYONCIL became the first FDA-approved mesenchymal stromal cell therapy in the U.S.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.94% to hover around $69.92 per barrel.
The gold spot index fell by 0.82% to $2,631.59 per ounce. The Dollar Index was down 0.12% to 107.893 level.
Asian markets declined on Thursday, as Hong Kong&#8217;s Hang Seng, South Korea&#8217;s Kospi, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, and Australia&#8217;s ASX 200 index fell, while China&#8217;s CSI 300 index ended marginally higher.
Most European markets were also trading lower.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42571821/why-sangamo-therapeutics-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket">Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Market Summary

Futures

Federal Reserve

Pre-Market Outlook

Movers

Trading Ideas

KULR

MESO

SGMO

US Stocks Likely To Open Higher After Plunging On Powell's Hawkish Comments: Analyst Calls It A 'Healthy' Reaction From An 'Overly Optimistic' Market

Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile

ARMP

Armata Pharmaceuticals Announced Topline Results From Its Phase 2 Tailwind Trial Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Non-cystic Fibrosis Bronchiectasis Patients

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

Reiteration

SRPT

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

Citigroup analyst James Hardiman initiates coverage on Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Buy rating and announces Price Target of $54.

Initiation

Citigroup Initiates Coverage On Viking Holdings with Buy Rating, Announces Price Target of $54

MASS

908 Devices And Getinge Announce Their Collaboration To Integrate Getinge's Bioreactors With 908 Devices' MAVEN For Automated Control Of Glucose And Lactate Levels In Cell Cultures

ECD Automotive Design: An Alternative Automotive Manufacturing Opportunity

ECDA

ECDAW

Press Releases

Project Wasatch:  ECD Automotive Design's Newest One-Of-A-Kind Defender 90 Fully Restored and Ready for Utah's Urban Driving and Unique Landscapes

ECD Auto Design Announces Record Sales Price for a Custom Defender

ECD Automotive Design Flexes Manufacturing Muscle: Hits the Road to Bring Design Experience and Bespoke Vehicles to Clients' Backyards

From Track to World-Class Production: ECD Automotive Design's Mack Besser's Passion for Jaguar E-Types Ignites Modernization Movement

ECD Auto Design to Acquire Brand New Muscle Car Assets

Snow-Capped Adventure: Project Catamount Brings Skiing Excitement to Upstate Washington!

Project Scottsdale Commission, ECD Auto Design's Newest Jaguar E-Type EV Hums Across the Arizona Streets With 300 HP Under Its Hood

ECD Auto Design Revolutionizes American Muscle: Classic Ford Mustang Joins Iconic Lineup

ECD Auto Design Announces Funding for Growth Initiatives

Thunder Power Holdings, Inc. - Common Stock

Thunder Power Holdings

Cenntro

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Envirotech Vehicles

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

General Motors

Canoo

Honda Motor Co

Lucid Gr

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

Mullen Automotive

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

ECD Automotive Design

News

Latest news for ECD Automotive Design (NASDAQ:ECDAW) Stock

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga